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Abstract 
It has been shown extensively that glycosaminoglycan (GAG)-protein interactions can induce, 
accelerate and impede the clearance of amyloid fibrils associated with systemic and localised 
amyloidosis. Obtaining molecular details of these interactions is fundamental to our 
understanding of amyloid disease. Consequently, there is a need for analytical approaches that 
can identify protein conformational transitions and simultaneously characterise heparin 
interactions. By combining Raman spectroscopy with 2D perturbation correlation moving 
window (2DPCMW) analysis we have successfully identified changes in protein secondary 
structure during pH- and heparin-induced fibril formation of apolipoprotein A-I (apoA-I) 
associated with atherosclerosis. Furthermore, from the 2DPCMW we have identified peak 
shifts and intensity variations in Raman peaks arising from different heparan sulfate moieties, 
indicating that protein-heparin interactions vary at different heparin concentrations. Raman 
spectroscopy thus reveals new mechanistic insights into the role of GAGs during amyloid fibril 




Amyloidosis is a collection of protein misfolding diseases, characterised by a build-up of 
insoluble protein fibrils with a highly conserved cross-β structure.1,2 Amyloid deposits in tissue 
are associated ubiquitously with glycosaminoglycan (GAG) polysaccharides, and these clinical 
observations have provoked much research into the possible roles and mechanisms of GAGS 
in fibril formation.  Heparin, a highly sulfated GAG and analogue of heparan sulfate (HS), has 
been extensively shown to enhance fibril formation, fibril stability and potentially decrease 
amyloid toxicity in several amyloidogenic proteins including α-synuclein, amylin, Aβ peptide 
and tau.3-8 GAGs have also been shown to promote formation of amyloid in proteins with no 
natural propensity to form amyloid.7,9,10 Extensive studies of heparin and HS binding have 
revealed that accelerated fibril formation is closely associated with electrostatic interactions 
and sulfate moieties, with heparin acting as a scaffold for the assembly of protein fibrils.3,6,11-
13 Fibril formation is suppressed with the removal of sulfate groups from heparin and the 
addition of a large excess of magnesium or calcium ions, indicating the importance of the 
electrostatic interactions that occur between the GAG and basic amino acid side chains of the 
proteins.7,12,13 However, despite continuing investigation, and the vast body of data associating 
heparin and other GAGs with amyloidosis, little is known about the specific mechanism 
involved in heparin-induced fibril formation, or indeed whether there is a common mechanism 
across the entire amyloid proteome.5-7,13 There is a shortage of techniques that can observe the 
molecular details of GAGs in heterogeneous and insoluble amyloid deposits without recourse 
to isotopic or fluorescent labelling of the GAG component. Here we show that Raman 
spectroscopy can simultaneously monitor heparin interactions with changes in protein 
conformation to enable detailed structural characterisation of heparin-induced amyloid 
formation. 
The large amount of structural information available from Raman spectra of proteins makes it 
an ideal technique for monitoring even small alterations in protein conformations, including 
changes in the secondary structure (α-helical, β-structure and disordered elements) as well as 
exposure of side chain residues and binding regions.14-17 The application of 2D perturbation 
correlation moving windows (2DPCMW), a cross-correlation technique that improves the 
visualisation of significant spectral variations from perturbation-induced Raman data,18-20 
enables these small spectral changes to be easily identified and related to perturbation transition 
points, e.g. specific pH, temperature or ligand concentration that induce protein conformational 
changes.17,20,21 A key advantage of 2DPCMW is that rather than trying to separately compare 
one spectrum against another the data can be sectioned into ‘windows’ which enable 
conformation transitions associated with perturbation ranges to be identified. Furthermore, 
previous Raman studies have assigned specific Raman peaks to the different HS moieties, 
including N-sulfate (~1038 cm-1), 6-O-sulfate (~1056 cm-1) and 2-O-sulfate (~1065 cm-1)22-24 
therefore, it should be possible to determine spectral variations that arise from both heparin and 
protein structures simultaneously as heparin concentration is perturbed.  
We demonstrate here the sensitivity of Raman spectroscopy combined with 2DPCMW for the 
investigation of heparin-amyloid interactions, using as a pathologically-relevant example 
apolipoprotein A-I (apoA-I), the main protein component of high-density lipoprotein (HDL) 
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complexes, also linked with cardiovascular disease.13,25-27 Although ~95 % of apoA-I 
circulating in the body is associated in HDL particles28 the remaining 5 % is able to misfold 
into the amyloid species with the potential to accumulate in atherosclerotic plaques, 
contributing to cardiovascular disease by reduced cholesterol transport, increased plaque 
burden and instability.27 Fibril formation and aggregation of apoA-I is accelerated under acidic 
conditions29 or following oxidation,30 and the insoluble apoA-I aggregates have been shown to 
consist of a combination of α-helical and β-sheet components.25 Raman spectroscopy with 
2DPCMW is sensitive to spectral changes arising simultaneously from both the protein and 
heparin’s sulfate moieties during amyloid formation. A unique and powerful advantage of the 
technique is its ability to directly compare spectral snapshots at increasing concentration steps 
to identify conformational transitions in both protein and heparin as they interact providing a   
methodology  applicable to further studies of many different GAGs and the 30 or so proteins 




Expression of human apoA-I (2-243), referred to as apoA-I for the duration of this paper, was 
carried out following previously published methods.25,31,32 Briefly, an N-terminally His tagged 
apoA-I (E2D) fusion peptide was expressed in E.Coli BL21 cells (Agilent Technologies) under 
the control of the T7 lac operon.  Following induction with IPTG for 5 hours, the cells were 
harvested by centrifugation at 5,000 g and resuspended in cell lysis buffer [6 M GnHCl, 20 
mM NaH2PO4, 0.5 M NaCl (pH 7.4)] and sonicated. Cell debris was removed by centrifugation 
prior to loading the lysis solution onto a 20 mL His Trap column (GE Healthcare). The column 
was washed with 20 mM NaH2PO4, 0.5 M NaCl (pH 7.4) with increasing concentrations of 
imidazole. ApoA-I was eluted from the column with 20 mM NaH2PO4, 0.5 M NaCl, 500 mM 
imidazole (pH 7.4). Fractions containing the highest protein content were pooled and dialysed 
against 20 mM Tris, 1 mM benzamidine, 1mM ethylenediaminetetraacetic acid (pH 7). The 
apoA-I fusion peptide was incubated in 45 % formic acid at 55 °C for 5 hours, in order to 
facilitate the removal of the N-terminal His tag via the acid labile Asp(2)-Pro(3) bond 
introduced by the E2D mutation. This resulted in an apoA-I peptide, lacking the Glu-1 Asp-2 
residues. This protein was isolated from the formic acid and the N-terminal his tag peptide via 
dialysis against Tris buffer, followed by dialysis into McIlvaine buffer [165 mM Na2HPO4, 
17.6 mM citrate (pH 7). 
ApoA-I Aggregation 
Aggregation of apoA-I followed the conditions established in previous work.25 200 μL of 
apoA-I (36 μM) was incubated with increasing concentration of heparin sodium salt (14-15 
kDa Sigma Aldrich) ranging from zero to five times molar excess in McIlvaine buffer (165 
mM Na2HPO4, 17.6 mM citrate (pH 7). Aggregation was induced with addition of a pre-
determined volume of concentrated hydrochloric acid (37 %) in order to reduce the sample to 
pH 4. Samples at pH 7 were maintained in the buffer without the addition of acid, and heparin 
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controls were prepared by resuspending the solid heparin directly into McIlvaine buffer at pH 
7, with the pH adjusted by addition of HCl accordingly. All samples (including samples at pH 
7 and test samples of heparin without apoA-I) were then incubated at 37 °C for 3 days with 
agitation. Protein samples at pH 7 and the heparin control samples were used directly after 
incubation. From the pH 4 samples, fibrillar apoA-I was then pelleted by centrifugation, and 
the excess monomeric apoA-I, heparin and buffer was removed. The fibrils were washed 3 
times with McIlvaine buffer at pH 4. The apoA-I fibrils were resuspended in 50 μL McIlvaine 
pH 4.  
Raman spectroscopy 
Previous studies have shown that apoA-I is relatively stable in its native, predominantly α-
helical, form at pH 7, but under acidic conditions (e.g., pH 4) it slowly assembles into insoluble 
fibrils with a high β-sheet content, and this process is accelerated considerably by the addition 
of heparin.30 In order to directly compare samples prepared at pH 7 and pH 4 (with and without 
the addition of heparin) 30 µL of the solution, including any aggregated material, was deposited 
onto a CaFl Raman window using 3 repeat 10 µL drops and left to dry at room temperature 
forming a thin layer / film for analysis.  
All Raman spectra were collected using a confocal Raman system (InVia, Renishaw plc, 
Wotton-Under edge, UK), coupled to a 785 nm wavelength laser. Spectra were collected from 
the dried films using a 50x objective with a laser power at the sample of ~10 mW, exposure 
time of 10 s with 12 accumulations (total collection time 2 min). 5 repeat spectra were collected 
and averaged from different locations within an identified region of the film e.g. either protein, 
buffer or heparin regions as discussed in more detail in Results and Discussion (Figure 1). 
Data Processing 
All data processing and 2D correlation analysis was carried out using Matlab (version R2018a) 
using in-house toolboxes. After cosmic spike removal all data were smoothed using a triangular 
average and baseline corrected using asymmetric least squares algorithm. For direct 
comparison of the apoA-I spectra a further pre-processing step of scaling to the maximum peak 
intensity of the invariant Raman peak at 1447 cm-1 (arising from CH2 groups) was required. 
For the heparin and buffer controls, as no protein was present, normalisation was carried out 
using standard normal variate (SNV) before smoothing and baseline correction.  
 
Results and Discussion 
Protein film formation 
As the first step, 30 µL of apoA-I solution, was deposited onto a CaFl Raman window and left 
to dry at room temperature forming a thin film for analysis. An extensively reported issue with 
film formation of protein solutions is heterogeneity across the film due to the formation of a 
‘coffee ring’, which can be observed in Figures 1A and 1B displaying the white light images 
at x5 and x50 magnification of dried apoA-I fims.33-35 However, for the apoA-I protein samples, 
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film formation provided the advantage of separating the protein from the buffer enabling 
Raman spectra of apoA-I with minimal buffer interference to be acquired. The spatial 
distribution of the protein can be exploited further to separate the signals from aggregated and 
unaggregated protein.    
 
Figure 1. Thin film Raman spectra of apoA-I alone at pH 7 and pH 4 in the absence of heparin. 
(A) pH 7 and (B) pH 4 white light images captured using a 5x and 50x objective. (C) Spectra 
recorded from the pH 7 film the inner region (red), the darker regions (blue) and the very outer 
ring (black) as indicated on the white light image. (D) Spectra recorded from the pH 4 film 
from the bright regions (black), outer ring (brown) inner ring (red) and darker central regions 
(blue) as indicated on the white light image. All spectra have been smoothed and baseline 
corrected only. 
 
ApoA-I is stabilised in its native, soluble form at pH 7 in the absence of heparin.  In Figure 1C 
spectra collected from the outer ring of the pH 7 apoA-I  film have distinct protein peaks 
including strong amide I (~1630-1700 cm-1), amide III (~1230-1340 cm-1) and backbone 
(~870-1150 cm-1) assigned peaks (Table 1), whereas spectra collected from the more central 
and darker regions have very similar spectral features to the Raman spectra recorded from the 
buffer only samples (Figure SI1). Hence, monomeric, soluble protein appears to freely diffuse 
from the central region to the outer perimeter. ApoA-I can be induced to undergo slow 
aggregation at pH 4 in the absence of heparin.  The white light image of dried apoA-I at pH 4 
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(at x5 magnification) (Figure 1 B) appears to show a similar coffee ring effect. However, 
protein signals were not observed in the spectra collected from the outer region at pH 4 (Figure 
1C). Further observations at x50 magnification revealed ‘bright’ regions in the white light 
images in various locations throughout the entire pH 4 film not observed at pH 7. Spectra 
acquired from the bright areas revealed strong protein peaks whilst spectra acquired from inner 
darker regions contained only buffer peaks. The lack of movement to the outer coffee ring is 
most likely due to the insoluble nature of the apoA-I aggregates at pH 4. The ability to spatially 
segregate and spectroscopically detect monomeric and aggregated protein is a unique 
advantage of this method that is broadly applicable to many amyloid systems, particularly 
mixtures of aggregated and unaggregated material.  
As a result of these important different drying effects during film formation apoA-I spectra of 
samples prepared at pH 7 were acquired from the outer ring of the film and for samples 
prepared at pH 4 spectra were acquired from bright regions across the sample film. Although 
potentially time consuming, as specific locations need to be determined across the sample, the 
formation of the coffee ring does allow for a direct comparison of aggregated and non-
aggregated protein samples.  
 
Table 1. Proposed Raman peak assignments for apoA-I and heparin. 
Assignment Wavenumber (cm-1) Structure 
Protein 
amide I, C=O stretch 
 (1630-1700 cm-1) 
 
amide III,  
N-H in plane, 




















β-sheet, narrows with aggregation8,16  





Disordered structure39,41  
β-sheet8,42 
 
Intermolecular sheet interactions42,43  
Disordered structure42,43 
α-helix43,44  









Tyr Fermi Double45,46  
Tyr Fermi Double45,46  




N-sulfate, symmetric S-O stretch22,23  




2-O-sulfate, symmetric S-O 
stretch22,23 
 
Figure 2. Averaged Raman spectra (n=5) of apoA-I acquired from thin films prepared at pH 7 
(blue) and pH 4 (red).  
Figure 2 displays the averaged Raman spectra of apoA-I prepared at pH 7 and pH 4. A large 
number of consistent protein features can be observed in both spectra, including Raman peaks 
arising from β-structure, α-helix and side chain orientation of tyrosine, tryptophan and 
phenylalanine (Table 1). The Raman spectrum of apoA-I at pH 7 indicates the predominance 
of α-helical structure with intense peaks observed at 932 and 1652 cm-1 which agrees with 
previous studies reporting apoA-I at pH 7 as having over 50% α-helical structure.25 When 
compared with the Raman spectra acquired at pH 4 a decrease in peak intensity can be observed 
at ~932 cm-1 indicating a reduction but not complete loss of α-helical secondary structure with 
changing pH. In the amide I region, arising from C=O stretch of the peptide backbone, there is 
a loss of intensity at 1652 cm-1 with a shift to 1665 cm-1. This wavenumber shift, along with 
the increase in intensity observed at 1240 cm-1 arising from C-N stretch and N-H bend, 
indicates an increase in β-sheet and potentially disordered structure at pH 4 compared to pH 7 
(Table 1). Similar structural changes were also reported after investigations into apoA-I 
aggregation by SRCD where fitting of spectra suggested a partial loss of helical content and a 
gain of β-sheet and disordered elements.25 In Figure 2 the peak at 950 cm-1 assigned to 
disordered structure is more distinct in the spectrum acquired at pH 4 compared to pH 7 and 
may also indicate an increase is disordered elements.  
 
Heparin-induced spectral variation 
As previously discussed, heparin binding to several amyloidogenic proteins have been shown 
to rapidly induce amyloid formation.; CD and NMR spectroscopy can determine heparin-
induced structural changes and map binding sites on the fibrils,47   but cannot easily visualise  
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bound or other GAGs, and this is where Raman spectroscopy can provide new insights into the 
role of heparin in the aggregation process. In the case of ApoA-I, the protein undergoes 
instantaneous aggregation into amyloid-like fibrils in the presence of heparin at pH 4. Figure 
3A displays the Raman spectra of apoA-I at pH 4 and pH 7, with and without heparin, at a 1:5 
molar excess concentration. When the spectra of ApoA-I at pH 4 with and without heparin are 
compared heparin assigned peaks in the region ~1020-1100 cm-1 (Figure SI2) can be clearly 
observed alongside variations in peaks assigned to protein structural features, demonstrating 
the ability of Raman spectroscopy to determine  heparin interactions and conformational 
changes  simultaneously.  A decrease in peak intensity can be observed at 1314 and 1340 cm-1 
as well as a large increase in the peak intensity at 1240 cm-1 indicating a greater loss of α-
helical structure and an increase in β-sheet at pH 4with the addition of heparin.  
 
Interestingly, heparin peaks are not observed at pH 7 even at a 1:5 molar excess over apoA-I 
(Figure 3A) and protein assigned peaks show no variation with the addition of heparin 
suggesting a lack of protein-heparin interaction. The white light images of the pH 7 films 
exhibit two outer rings and a dark inner region. Spectra from these three regions indicate that 
heparin separates from the protein and buffer during film formation at pH 7. In Figure 3B 
heparin spectral features in the region 1020-1100 cm-1 can be observed in the spectra collected 
from the inner ring of the dried film but no protein features are observed. In contrast, spectra 
collected from the very outer region display only protein features with no heparin assigned 
peaks observed suggesting complete separation of protein from heparin during film formation. 
The spectrum from this region contains no signature peaks signifying β-sheet formation, 
implying that the protein retains its predominantly α-helical fold. Consequently, heparin binds 
weakly or not at all to apoA-I in its native form at pH 7, whereas at pH 4, the combination of 
heparin with reduced α-helical structure, increased disordered and β-structures results in further 
aggregation. At pH 4 the heparin peaks colocalize with the protein peaks at all positions, 
indicating that heparin is incorporated into the fibrils. Heparin binding must therefore occur 
only after partial structural rearrangement in the protein induced by low pH, or as a result of 




Figure 3. Thin film Raman spectra of apoA-I in the presence of heparin. (A) Average Raman 
spectra (n=5) of apoA-I with (1:5) and without (1:0) heparin at a 1:5 molar ratio prepared at 
pH 7 and pH 4.(B) White light images of apoA-I:heparin films at pH 7 with 5 molar excess of 
heparin and averaged Raman spectra (n=5) acquired from the very outer ring (black), inner ring 
(red) and darker regions (blue). 
 
2D Correlation analysis 
Further information about heparin-protein interactions during aggregation can be gained using 
2D correlation spectroscopy (2DCOS). 2D correlation spectroscopy (2DCOS) is a cross-
correlation technique that simplifies a spectral data set obtained over some systematically 
varied perturbation, such as incremented temperature, concentration or pH,  by displaying 
relative similarities and differences as contour plots.19,20 In particular, 2D perturbation 
correlation moving windows (2DPCMW) contour plots have the advantage of directly relating 
spectral variations to the perturbation by separating the data into smaller windows to locate key 
transitional points.17,18,20 2DPCMW contour plots are usually displayed as a function of spectral 
wavenumber against average translating perturbation resulting in groups of contours that are 
either positive or negative in value, with distinct shapes that indicate the extent and direction 
of spectral variations occurring at the corresponding peak wavenumber.  
Here, we demonstrate that 2DPCMW provides insights into the molecular details 
accompanying amyloid formation in the presence of increasing concentrations of heparin, from 
the perspective of the protein and the GAG simultaneously.  Figure 4 displays the 2DPCMW 
of heparin-concentration induced spectral variations for apoA-I at pH 4 where positive contours 
(shaded red) indicate increasing peak intensity and negative contours (shaded blue) indicate 
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decreasing peak intensity at apoA-I:heparin ratio ranges with the relative extent of intensity 
change indicated by the number of contours.  
 
Figure 4. 2DPCMW plots of heparin-induced aggregation in apoA-I at pH 4. Heparin 
concentration was varied (A) from 0 to 5 excess molar concentration of heparin and (B) 0 to 
molar equivalence with apoA-I. 2DPCMW plotted as a function of spectral wavenumber and 
average translating window ratio. Contours shaded red indicate peaks that are increasing in 
intensity with increasing heparin concentration while blue shading indicates decreasing peak 
intensity with increasing concentration.  
 
In Figure 4A where the apoA-I:heparin molar ratio was increased in 0.5 concentration steps up 
to a 5-fold molar excess over apoA-I, the majority of contours, and therefore spectral variations, 
are observed between apoA-I:heparin molar ratios of 1:0 and 1:1 with very few contours 
observed above 1:1 ratio. Small contours can be observed at 898 and 1020-1100 cm-1 at 1:2.5-
1:3 excess molar ratio, which may be due to the slight influence of buffer or heparin peaks 
observed in the protein spectra as a result of reduced separation during thin film formation at 
the higher apoA-I:heparin ratios (Figures SI3 and SI4). The lack of further contours in the 
heparin assigned region 1020-1100 cm-1 suggest that no additional heparin colocalises with the 
insoluble apoA-I at these higher ratios and that free heparin may either interact with the buffer 
or dry separately during film formation. Hence, the 2DPCMW method indicates that no further 
binding occurs above the apoA-I:heparin molar ratio of 1:1. 
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As the majority of spectral variations are observed below a ratio of 1:1 additional spectra were 
collected in 0.2 steps (example spectra shown in Figure SI5) and the 2DPCMW is shown in 
Figure 4B, where three potential possible structural transitions can be identified as the heparin 
concentration is increased. 
With the exception of the buffer and heparin assigned peaks at 898 and 1020-1100 cm-1, all 
major variations in the spectra cease above the molar ratio of 1:0.6 suggesting that the majority 
of protein structural changes take place below this concentration. It should be noted that the 
amyloid:heparin samples were obtained after 3 days of incubation and the spectra detect the 
species present at end-point of the aggregation process. Negative contours are assigned to the 
loss of α-helix and positive contours assigned to β-sheet formation and aromatic side chain 
reorientation (Table 2). These structural changes are not observed by CD spectroscopy because 
the rapid precipitation of the protein during aggregation gives rise to a considerable loss of 
signal (Figure SI7). When examined closely the two sets of positive contours arising from β-
sheet assigned peaks stop at different apoA-I:heparin ratios with the peak at 1668 cm-1 no 
longer changing in intensity after ~1:0.4 whilst the peak at 1240 cm-1 continues to increase in 
intensity until a ratio of 1:0.6, suggesting two possible transition stages one from 0-0.4 and a 
second from 0.4-0.6. Identifying these separate but subtle differences in conformational 
transitions is difficult from visual inspection of the spectra alone (Figurs SI5) demonstrating 
the potential of 2DPCMW to aid spectral analysis of data sets. A previous Raman study of pH-
induced amyloid formation in α-synuclein in the absence of heparin reported similar 
discrepancies in behaviour of the two β-sheet assigned peaks associated with the formation of 
longer fibrils.8  As previously stated, peaks in the amide I region (1630-1700 cm-1) arise from 
C=O stretching whilst peaks in the amide III region (1230-1340 cm-1) arise from C-N stretching 
and N-H bending. The continued increase in intensity at 1240 cm-1 compared to the 1668 cm-1 
may indicate a change, or elongation, in fibril formation with increasing heparin concentration. 
 






828  0.0-0.5 Tyrosine side chain reorientation 
1003  0.0-0.4 Phenylalanine side chain 
reorientation 
1240  0.0-0.6 -sheet formation 
1314  0.1-0.6 Loss of -helix 
1652  0.1-0.6 Loss of -helix 
1668  0.0-0.4 -sheet formation 
 
As well as reporting heparin-induced protein conformational changes, correlation analysis 
reveals new insights from the perspective of heparin. Interestingly, in the 2DPCMW plot 
(Figure 4B) in the first transition stage from 1:0 to 1:0.4 molar ratio, distinct contours from 
heparin assigned peaks can be observed at 1038 and 1056 cm-1; however, above 1:0.4 ratio 
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these peaks merge and shift to 1065 cm-1 which continues to the ratio of 1:1. In the spectrum 
of heparin alone (Figure SI2), potential overlapping peaks can be observed at 1038, 1056 and 
1065 cm-1 (Figure SI4), which have beenassigned to the N-sulfate, 6-O-sulfate, and 2-O-sulfate 
of the symmetric S-O stretch, respectively.22-24 One well documented advantage of 2DCOS is 
the ability to identify differences in behaviour in overlapping bands which are difficult to 
determine in the spectra. Raman spectra from thin films of heparin only, at concentrations 
comparable to those used in the apoA-I:heparin measurements show a typical increase in peak 
intensity with increasing concentration (Figure SI6), butno shift in peak position or intensity 
variation between the overlapping peaks can be observed in absence of apoA-I. The changes 
seen in the presence of protein most likely arise from differences in heparin binding to apoA-I 
above and below the molar ratio of 1:0.4.  
A mechanism can be proposed that accounts for the heparin-dependent changes in the Raman 
spectra. Native folded apoA-I is a stable helical bundle and does not have exposed binding sites 
for heparin, but acidic conditions may stabilise the so-called “beta-clasp” structure of lipid-free 
apoA-I in which four anti-parallel β-strands are proposed to form at the N- and C-termini.48,49 
Lower concentrations of heparin may bind to these regions and nucleate self-assembly of the 
strands, rapidly exhausting the concentration of free heparin. At higher concentrations the 
excess heparin may bind to different sites on the elongating fibrils, hence accounting for the 
different spectral changes observed at higher heparin:apoA-I molar ratios. 
 
Conclusion 
We have demonstrated the unique sensitivity of Raman spectroscopy combined with 2D 
correlation analysis, in particular 2DPCMW, to investigate the interactions between the GAG-
proxy heparin and amyloid fibrils. The methodology offers new insights the structure and 
composition of amyloid fibrils and is complementary to more established structural methods. 
The spectra report on both the protein and saccharide components of the insoluble fibrils 
without modification or labelling. In the specific example studied, a partial loss of helical 
content in apoA-I is observed alongside an increase β-sheet and disordered elements and the 
importance of each specific sulfate moiety in directing fibril formation can be identified. 
Perturbations of bands 1100 and 1400 cm-1 have been attributed to conformational changes in 
the rings.50 Here, the observed changes may be due to a shift in the dynamic equilibrium 
between the 1C4 chair and 
2S0 skew boat forms (67:33 
1C4:
2S0).  This could be tested further 
using model compounds of known conformation. 
A unique advantage of the method is the ability to spatially separate monomeric protein from 
aggregated protein and from free heparin, revealing new insights into the heparin binding 
mechanism. It is envisaged that this method can equally be applied to other GAG-dependent 
amyloidogenic proteins, such as tau, amyloid- and functional amyloid systems, to report 
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